ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 440

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment

Yusuke Miwa1, Ryo Takahashi1, Airi Maeoka1, Shinichiro Nishimi1, Nao Oguro1, Sho Ishii1, Mika Kobuna1, Takahiro Tokunaga1, Masayu Umemura1, Tsuyoshi Kasama1, Katsunori Inagaki2 and Yoichi Toyoshima3, 1Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, 2Department of Orthopedics, Showa University School of Med, Tokyo, Japan, 3Showa University School of Med, Shinagawa-ku Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic agents, Health Assessment Questionnaire, remission and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic agents are highly effective for rheumatoid arthritis (RA); however, not all cases achieve health assessment questionnaire (HAQ) remission. Although previous studies have reported the prognostic factors, there is no report on predictive factors for HAQ remission. To study predictive factors for HAQ remission, which is one of the treatment goals in RA, after using biologic agents for 6 months.

Methods:

The subjects were 333 RA patients treated with biologic agents for 6 months. The following patient’s characteristics were investigated: age, gender, the number of previous drugs, disease duration, the type of biologic agents, baseline steroid dosage, MTX dosage, serum RF, MMP-3, ACPA, TNF-α, and IL-6. For evaluation we used SDAI for RA disease activity, HAQ for ADL, Short Form (SF)-36 for QOL, and Hamilton Depression Rating Scale (HAM-D) or Self-rating depression scale (SDS) for depression status. HAQ remission was defined by HAQ�…0.5 after 6 months of treatment. The subjects were divided into two groups: patients with HAQ�…0.5 and patients with HAQ>0.5 at 6 months, and a retrospective study was conducted. 101 patients were excluded from the study due to loss to 6-month follow-up, and a total of 232 patients were analyzed.

Results: Compared with a group of RA patients without HAQ remission (n=68), a group of patients with HAQ remission (n=164) had younger age (54.8 ± 15.2 vs. 61.8 ± 13.3, p=0.0011), lower baseline steroid dosage (3.4 ± 3.7mg vs. 4.5 ± 3.5mg, p=0.037), lower serum MMP-3 (196 ± 234 ng/ml vs. 321 ± 551, p=0.047), lower SDAI (22.5 ± 13.4 vs. 32.1 ± 12.9, p<0.001), lower HAQ (0.39 ± 0.51 vs. 1.08 ± 0.54, p<0.001), higher SF-36 (p<0.05 in all categories), lower SDS (40.4 ± 9.9 vs. 43.5 ± 9.2, p=0.033), and lower HAM-D (5.0 ± 4.3 vs. 8.4 ± 5.0�Ap<0.001) were detected based on univariate analysis. On the other hand, only in lower HAQ score (p=0.0001) and “mental health” item of the SF-36 (p=0.0189) were detected based on logistic regression analysis.

Conclusion:

It was suggested that RA patients with lower HAQ and lower depression scores at baseline are more likely to achieve HAQ remission with biologic treatment.


Disclosure: Y. Miwa, None; R. Takahashi, None; A. Maeoka, None; S. Nishimi, None; N. Oguro, None; S. Ishii, None; M. Kobuna, None; T. Tokunaga, None; M. Umemura, None; T. Kasama, None; K. Inagaki, None; Y. Toyoshima, None.

To cite this abstract in AMA style:

Miwa Y, Takahashi R, Maeoka A, Nishimi S, Oguro N, Ishii S, Kobuna M, Tokunaga T, Umemura M, Kasama T, Inagaki K, Toyoshima Y. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-haq-remission-with-6-months-of-biologic-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-haq-remission-with-6-months-of-biologic-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology